ASCCP

(redirected from American Society for Colposcopy and Cervical Pathology)
AcronymDefinition
ASCCPAmerican Society for Colposcopy and Cervical Pathology
References in periodicals archive ?
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.
Separate guidelines from the American Cancer Society, the American Society for Clinical Pathology, and the American Society for Colposcopy and Cervical Pathology recommend a Pap test every 3 years in women aged 21-29 years, with HPV testing only if needed after an abnormal Pap test result.
For reproductive-aged women with CIN 2 and adequate colposcopy, the American Society for Colposcopy and Cervical Pathology supports either monitoring with cytology and colposcopy every 6 months for a year or excisional treatment.
High-risk human papillomavirus testing is acceptable as a primary approach to cervical cancer screening in women aged 25 years and older, according to interim clinical guidance from an expert panel convened by the Society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology.
Saslow D, Solomon D, Lawson HW, et al; American Cancer Society, American Society for Colposcopy and Cervical Pathology, American Society for Clinical Pathology.
Wright said at the conference sponsored by the American Society for Colposcopy and Cervical Pathology (ASCCP).
American Society for Colposcopy and Cervical Pathology consensus guidelines for the management of women with CIN were published in 2003.
Recommendations in this set of guidelines differ slightly from those published in 2015 by the Society of Gynecologic Oncology (SGO) and the American Society for Colposcopy and Cervical Pathology (ASCCP).
In January 2015, the Society of Gynecologic Oncology (SGO) and the American Society for Colposcopy and Cervical Pathology (ASCCP), with input from five other professional associations, published interim clinical guidance on the use of primary high-risk human papillomavirus (hrHPV) testing in cervical cancer screening.
In addition to the USPSTF guidelines, the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology (ACS/ASCCP/ASCP) recently have published cervical cancer prevention guidelines that similarly extend the intervals between screenings, they noted.
As summarized by the HPV DNA Test Utilization Statement, (12)--based on the consensus guidelines developed by the American Society for Colposcopy and Cervical Pathology (4) and endorsed by the American Cancer Society, American Society for Clinical Pathology, American Society for Colposcopy and Cervical Pathology, American Society of Cytopathology, American Society for Cytotechnology, College of American Pathologists, International Academy of Cytology, and Papanicolaou Society of Cytopathology--there is clear, documented benefit for HPV testing in the circumstances listed in the document.
Full browser ?